* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discove...
* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was gene...
* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors ...
Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patien...
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK...
Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CA...
